Boston Scientific Corp. vs. Pro-Dex Inc New
Boston Scientific Corp. (BSX) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| BSX | PDEX | |
|---|---|---|
| Market Cap | $75.11 billion | $214.39 million |
| Revenue (TTM) | $21.00 billion | $72.10 million |
| Net Income (TTM) | $3.67 billion | $2.52 million |
BSX leads on 3 of 3 size & scale factors.
Valuation
| BSX | PDEX | |
|---|---|---|
| P/E Ratio | 20.75 | 19.62 |
| Price / Book | 2.98 | 5.15 |
| Price / Sales | 3.58 | 2.97 |
PDEX leads on 2 of 3 valuation factors.
Profitability
| BSX | PDEX | |
|---|---|---|
| Net Margin | 17.47% | 3.49% |
| Return on Equity | 14.57% | 6.04% |
BSX leads on 2 of 2 profitability factors.
Risk & Sentiment
| BSX | PDEX | |
|---|---|---|
| Short Interest | 0.72% | 0.14% |
PDEX leads on 1 of 1 risk & sentiment factors.
Dig deeper: BSX overview, BSX financials, PDEX overview, PDEX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
